Ustekinumab for the treatment of adults with moderate to severe psoriasis

Review decision - September 2010 information

Appendix A: Decision paper presented to the Institute's Guidance Executive (PDF 105 KB)

Review proposal - August 2010 information

Appendix A: provisional matrix of stakeholders (PDF 29 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 285 KB)

NICE guidance recommends treatment for severe plaque psoriasis (PDF 70 KB)

Psoriasis - ustekinumab: final appraisal determination information

Psoriasis - ustekinumab: final appraisal determination (PDF 134 KB)

Response to consultee, commentator and public comments on the appraisal consultation document (ACD) (PDF 133 KB)

Consultee and commentator comments on the ACD

Janssen-Cilag (PDF 86 KB)

British Association of Dermatologists (PDF 28 KB)

Psoriasis and Psoriatic Arthritis Alliance (PDF 79 KB)

Royal College of Physicians (PDF 25 KB)

Royal College of Nursing (PDF 21 KB)

Department of Health (PDF 11 KB)

Dorset PCT (PDF 25 KB)

Welsh Assembly Government (PDF 27 KB)

Abbott Laboratories (PDF 189 KB)

Schering-Plough (PDF 30 KB)

Wyeth Pharmaceutical (PDF 28 KB)

Psoriasis - ustekinumab: appraisal consultation information

Psoriasis - ustekinumab: appraisal consultation document information

Psoriasis - ustekinumab: evaluation report

Psoriasis - ustekinumab: pre-meeting briefing (PDF 173 KB)

Psoriasis - ustekinumab: Evidence Review Group report (PDF 1.48 MB)

Psoriasis - ustekinumab: Non-manufacturer submissions

Psoriasis - ustekinumab: Non-manufacturer submissions - British Association of Dermatologists (PDF 53 KB)

Psoriasis - ustekinumab: Non-manufacturer submissions - Dorset PCT (PDF 62 KB)

Psoriasis - ustekinumab: Non-manufacturer submissions - The Psoriasis Association (PDF 49 KB)

Psoriasis - ustekinumab: Non-manufacturer submissions - The Psoriasis and Psoriatic Arthritis Alliance (PDF 51 KB)

Psoriasis - ustekinumab: Non-manufacturer submissions - The Royal College of Physicians (PDF 50 KB)

Psoriasis - ustekinumab: Manufacturer submission

Psoriasis - ustekinumab: Manufacturer submission - Janssen-Cilag (PDF 2.52 MB)

Psoriasis - ustekinumab: Manufacturer submission - NICE clarification letter (PDF 27 KB)

Psoriasis - ustekinumab: Manufacturer submission - Manufacturer response to clarification letter (PDF 416 KB)

Psoriasis - ustekinumab: Expert written personal statements

Psoriasis - ustekinumab: Expert written personal statements - Anstey information

Psoriasis - ustekinumab: Expert written personal statements - Anstey (PDF 20 KB)

Psoriasis - ustekinumab: Expert written personal statements - Barker information

Psoriasis - ustekinumab: Expert written personal statements - Barker (PDF 21 KB)

Psoriasis - ustekinumab: Expert written personal statements - Jobling information

Psoriasis - ustekinumab: Expert written personal statements - Jobling (PDF 20 KB)

Psoriasis - ustekinumab: Expert written personal statements - McAteer information

Psoriasis - ustekinumab: Expert written personal statements - McAteer (PDF 20 KB)

Psoriasis - ustekinumab: final scope (PDF 29 KB)

Psoriasis - ustekinumab: stakeholder comments on the draft remit (PDF 106 KB)

Psoriasis - ustekinumab: stakeholder comments on the provisional matrix of consultees and commentators (PDF 19 KB)